Orphazyme A/S (ORPH) reports that it received a "communication" from the FDA and will now price its IPO on Monday, September 28, with an expected October 1 closing date.
It does not explain the specific nature of the communication, only stating that it will amend its registration statement. The agency's acceptance of its marketing application for arimoclomol for Niemann-Pick disease Type C and its action date of March 17, 2021 are not affected.
The book for offering is fully covered.
https://seekingalpha.com/news/3617247-orphazyme-resets-ipo-date-to-september-28
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.